Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide

Next Previous
Trial Profile

Phase II Study of First Line Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 04 Nov 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Arsenic trioxide (Primary) ; Corticosteroids
  • Indications Graft-versus-host disease
  • Focus Therapeutic Use
  • Acronyms GvHD-ATO
  • Sponsors Medsenic

Most Recent Events

  • 28 Oct 2024 According to BioSenic Media Release, BioSenic released new in-depth analysis of its positive phase 2 clinical data in July 2024, for optimal administration scheme for its next late-stage trial of arsenic trioxide (ATO) targeting cGvHD.
  • 12 Mar 2024 According to BioSenic Media Release, company announces the publication of an open-access article describing an optimized schedule for administration of oral arsenic trioxide (OATO) treatment for chronic graft-versus-host disease (cGvHD), based on an earlier post-hoc analysis of Phase 2 data. The schedule will play an important role in the protocol for BioSenic's forthcoming pivotal Phase 3 clinical trial.
  • 27 Sep 2023 According to BioSenic Media Release, company erforms further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD. This analysis will be used to decide on the best oral ATO's posology for BioSenic's forthcoming phase 3 clinical trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top